anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This multi-center, prospective, non-controlled, consecutive cohort post market surveillance study will serve the purpose of confirming long-term safety and performance of the Hyperion® system. The performance of the Hyperion® THA System will be evaluated using standard scoring systems (Merle d'Aubigné Score, HOOS Score). Safety will be evaluated by adverse event reporting.

The study will be performed at 6 sites, enrolling in total 70 patients. Follow-up visits are planned after 3 to 6 month, 1, 2 and 5 years. The scores will be filled in pre-operatively and post-operatively until 5 years. In order to obtain mid- to long-term patient satisfaction data the patient questionnaire will be send to the patient at 7 and 10 years, additionally. Xrays will be done pre-operatively, immediate post-operatively and at each of the Follow-up visits.
A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
(1) Background: General nutrition knowledge is a fundamental pillar of well-being and healthy lifestyles. This study aimed to measure the general nutrition knowledge questionnaire (GNKQ) scores of overweight and obese participants who joined a pilot randomized controlled trial (RCT) and the association between changes in GNKQ scores and changes in anthropometric measures. (2) Methods: A total of 30 and 25 participants had completed the trial at the 3- and 6-month visits, respectively. All participants enrolled in a randomized controlled trial (RCT) and received a hypocaloric-tailored diet and three online nutrition education sessions over 6 months. The participants were randomly divided into two groups: an intervention group supported with weekly telemonitoring and monthly telehealth coaching vs. a control group. The Arabic-validated GNKQ was used, covering four sections: dietary recommendations; food groups and nutrient sources; healthy food choices; and associations between the diet-disease relationship and weight. (3) Results: The findings show that both the intervention and control groups showed improvements in GNKQ scores over time, with the intervention group demonstrating significant increases in overall nutrition knowledge and specific areas, such as the diet-disease relationship and weight management, at 3 months. In addition, changes in GNKQ scores had a significant negative association with BMI and visceral fat percentage. The findings underline the benefits of supporting dietary weight loss interventions with telemonitoring and telehealth coaching, suggesting that an increase in nutrition knowledge may relate to lower body fat metrics. Nevertheless, the small sample size and high attrition rate of participants were the main limitations of this study, such that large populations are required to confirm the reliability of the obtained findings.
FIELD: medicine. SUBSTANCE: method involves combining medicinal substance in therapeutic dose and potentiated medicinal preparation produced according to homeopathic method and having the same initial chemical formula. The medicinal ingredients are selectable in the same medicinal form. The medicinal remedy is biologically active substance taken in therapeutic dose and the same substance taken as potentiated homeopathic preparation. EFFECT: enhanced effectiveness in combining allopathic and homeopathic preparations. 3 cl
CivaSheet® is an FDA-cleared product from CivaTech Oncology®. It is a series of small radioactive palladium-103 (Pd-103) sources on bio-absorbable, flexible, bio-compatible membrane. The CivaSheet can be custom cut in the operating room. The CivaSheet is 5 cm wide by 15 cm long and has a rim to allow an easy surface to suture. This flexible device can contour the surgical cavity delivering highly conformal and targeted radiation dose. CivaSheet can deliver a very high radiation dose to the surgical margin to potential prevent local cancer recurrence.

Sarcoma patients have up to 80% local recurrence rates, depending on histology and location of disease presentation. CivaSheet will be implanted at the surgical margin follow tumor removal. Monitoring the rate of acute toxicity is the primary endpoint. Secondary endpoints include disease progression and recurrence rates.
It is a multi-center study. 3 different Spanish Freedivers Centres are included in the study (Madrid, Zaragoza, and Barcelona).

For each participant, exercise program started with one or the other program. Hence, both interventions were applied once with the participant randomly allocated to receive the same intervention. The trial included four study visits. Each exercise training program will be applied sessions per week during 4 weeks. Participants received baseline assessments at the beginning of nay intervention, and post-intervention assessments at the end of the fourth week. The wash-out period will be two weeks. After these two weeks participants switched intervention.
The intervention group (i.e. all eligible and consented residents of 2 NHs) will receive the OptiMEDs intervention: the combination of an electronic decision support tool (for the appraisal of potentially inappropriate medication use, anticholinergic use, or medications that can be de-prescribed in view of limited life expectancy) with focused nurse observations (using a list of potential medication-related symptoms based on the individual medication chart of the nursing home residents), that will serve as the basis during a multidisciplinary medication review with the input of GPs, trained community pharmacists and nurses.
OBJECTIVES: To compare the early and late mortality of patients that have suffered an ST segment elevation myocardial infarction (STEMI) and a non-ST segment elevated myocardialinfarction (NSTEMI).
METHODS: Retrospective study of patients treated at the Regional Clinical Hospital of Concepción from January the 1rst 2013 to December 31 rst 2015, with diagnostic of STEMI and NSTEMI that required coronary angioplasty during their hospitalization. Descriptive and multivariate analysis was performed to compare mortality rates between both populations before 30 days and in follow-up at 4 years.
RESULTS: 1838 patients were included with an average follow-up of 82 months. The population with STEMI was 921 and was younger, with a higher prevalence of arterial hypertension and smoking. The population with NSTEMI had a higher prevalence of diabetes mellitus, a lower glomerular filtration rate, and a higher incidence of left main coronary artery disease and chronic occlusions. At the end of follow-up, the overall survival rate was 76%, with no significant difference between the two groups. Patients with STEMI had twice the risk of dying in the first 30 days (Long Rank: 0.012). After 30 days, mortality was higher in the NSTEMI group (80.8% vs 75.6%).
CONCLUSIONS: This study did not show significant differences in overall mortality during prolonged follow-up of patients with STEMI and NSTEMI. The STEMI group had a higher risk of early death, while the NSTEMI group had higher long-term mortality.
The present invention relates to a protein component that contains proteins usually used in the food production, wherein at least 20 wt. % of these proteins have at least one phosphate residue covalently linked to the protein.  An amount of between 50 and 100 wt. % of the proteins having at least one covalently linked phosphate residue has been submitted to a dephosphorylation reaction during which between 20 and 100 wt. % of the covalently linked phosphate residue have been removed. This invention also relates to the use of this protein component for treating adult and young patients as well as infants or children of tender age affected by disorders of the gastric-intestinal motility, or even patients susceptible to be affected by reflux.
Patients mechanically ventilated with driving pressure between 15.1 and 18.0 cmH2O, until weaning conditions are satisfied. When weaning criteria are met, extubation may be attempted, it may either fail or not, or any other mechanical ventilation regime may be chosen, according to clinical practice.
The invention relates to a preparation technology and production method of an integrated Baihu decoction novel dosage form. The integrated novel dosage form comprises the following active ingredients in parts by weight: 18 parts of rhizoma anemarrhenae, 35 parts of gypsum, 6 parts of radix glycyrrhizae preparata and 18 parts of round shaped rice. The production process comprises the following steps: extraction in aqueous alcohol, ultrasonic grinding and extraction, microwave extraction, decoction in water and concentration, supersonic spray drying, high-pressure homogenizing, nanoscale grinding, nanoparticle preparation and the like. In the method, the stress is laid on the advantages of multi-synergy and multi-target effects of nano traditional Chinese medicines. After scale industrial production, the production cost can be substantially lowered, the product quality can be improved and the targeting and slow/controlled release properties of the medicines are stronger. After the novel dosage form is prepared into films, the films can be stuck to the skins of the human bodies and are used for treating the diseases through percutaneous absorption.
Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
Compositions comprising a calcium salt of L-leucovorin may be prepared that have a higher concentration of L-leucovorin than may be prepared using racemic leucovorin under similar conditions. Thus, some pharmaceutical compositions described herein may comprise a calcium salt of L-leucovorin at a relatively high concentration, such as at least about 15 mg/mL. Such a composition may be a stable aqueous solution, and may have near physiological pH, such as about 6 to about 8. Some pharmaceutical compositions may be substantially free of D-leucovorin, and may contain either: a) no EDTA, or b) less than about 1 mg/ml of EDTA. These compositions may be prepared, for example, by sonicating a mixture comprising the solid calcium salt of L-leucovorin and water. In some compositions, a calcium salt of L-leucovorin may be sufficiently soluble that it does not precipitate when it is injected.
PURPOSE:To obtain a solid cosmetic easily spreadable on the skin to give moist feeling and durable make-up by using an oil component and mica treated with higher fatty acid as essential components and preferably further incorporating a powdery component. CONSTITUTION:The objective solid cosmetic such as powdery foundation, eye color, pressed powder, loose powder, cheek color, powder lip and lip color is produced by using 5-25wt.% of mica treated with a higher fatty acid and 15-30wt.% of an oil component as essential components and preferably further using 30-60wt.% of a powdery component (e.g. titanium oxide, talc or nylon powder). The mica to be treated with a higher fatty acid is preferably muscovite and the higher fatty acid is preferably stearic acid. The ratio of the mica to the fatty acid is preferably 98:2 to 95:5. The treated mica can be produced by dissolving a higher fatty acid in a volatile oil, slowly pouring the obtained solution to dried mica under agitation, stirring at a low speed, distilling off the oil and subjecting the product to baking treatment.
Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
The prognosis of Takotsubo syndrome patients remains contentious, necessitating improved risk stratification for better management. While various clinical characteristics and parameters from transthoracic echocardiography have been associated with outcomes, none of the existing predictive scores incorporate cardiac magnetic resonance imaging (CMR) data, despite its ability to noninvasively assess tissue characterization. CMR offers a comprehensive evaluation of functional and structural changes, including an accurate assessment of right ventricular function. While CMR has been extensively studied for diagnostic purposes in Takotsubo syndrome, its role in prognosis is still debated. Emerging technologies like computed tomography show promise in myocardial characterization but lack robust investigation in prognostic roles. The EVOLUTION registry aims to address this gap by incorporating CMR parameters into a risk stratification score alongside clinical and transthoracic echocardiography data, with machine learning models also explored for enhanced outcome prediction. This initiative seeks to provide a more reliable predictive tool for the optimized management of Takotsubo syndrome patients. The main objective of this study is to enhance risk assessment in Takotsubo syndrome patients by incorporating CMR data alongside demographic, clinical, and transthoracic echocardiography parameters. Specifically, the aim is to analyze CMR data and their association with both short-term and long-term patient outcomes. Additionally, the effectiveness of the proposed risk stratification score for Takotsubo syndrome patients will be evaluated in comparison to existing scoring systems. Moreover, all available CMR, transthoracic echocardiography, and clinical variables will be utilized to develop machine learning models for predictive analysis
BACKGROUND: Prevalence of metabolic syndrome (MetS) increased from one-quarter to one-third of the U.S. adult population over 8 years and is spreading to young adults and Asian and Hispanic Americans. Diagnosed when >3 out of 5 cardiometabolic risk factors are present, there is widespread agreement that its fundamental roots are in a lifestyle characterized by poor dietary quality and physical inactivity. Past lifestyle trials for MetS produce benefits that have limited sustainability, suggesting the need for new treatment approaches.
METHODS: This is the design and baseline cohort of the Enhancing Lifestyles in the Metabolic Syndrome (ELM) multi-site trial. The trial tests the hypothesis that a habit-based lifestyle treatment offered over 6 months, followed by 18 monthly maintenance contacts, can produce 4 new diet, physical activity, and mindfulness habits and, if so, sustained MetS remission. The design is an individually randomized, partially clustered group treatment trial of 618 participants with the MetS recruited from 5 sites in the U.S. and randomized to a small group lifestyle treatment or an enhanced standard of care education comparator. The primary outcome is MetS remission at 24 months. Secondary outcomes compare arms at 6, 15, and 24 months on MetS components, lifestyle targets, weight, body mass index, hemoglobin A1c, LDL cholesterol, medications, quality of life, psychosocial factors, and cost-effectiveness.
RESULTS: The cohort of 618 participants was recruited by screening 14,817 over 2.5 years (screening to enrollment ratio 24:1). Recruitment exceeded the target of 600 despite 2 COVID-19 pauses. The mean age was 55.5 years, 24.3% were male, 25.5% were a racial minority, 9.7% identified as Hispanic, and 83.0% were classified as obese (body mass index >30). The most common MetS components were abdominal obesity (97.7%) and elevated blood pressure or antihypertensive medication (86.2%).
CONCLUSIONS: The geographic, sociodemographic, and clinical diversity of the cohort, combined with rigorous behavioral efficacy trial methods, will provide a conclusive answer to the question of whether this habit-based lifestyle program can produce sustained 24-month remission of the MetS and thereby help to curb a significant and growing public health problem.
Stimulator of Interferon Genes (STING) is essential for the inflammatory response to cytosolic DNA. Despite that aberrant activation of STING is linked to an increasing number of inflammatory diseases, the development of inhibitors has been challenging, with no compounds in the pipeline beyond the preclinical stage. We previously identified endogenous nitrated fatty acids as novel reversible STING inhibitors. With the aim of improving the specificity and efficacy of these compounds, we developed and tested a library of nitroalkene-based compounds for in vitro and in vivo STING inhibition. The structure-activity relationship study revealed a robustly improved electrophilicity and reduced degrees of freedom of nitroalkenes by conjugation with an aromatic moiety. The lead compounds CP-36 and CP-45, featuring a β-nitrostyrene moiety, potently inhibited STING activity in vitro and relieved STING-dependent inflammation in vivo. This validates the potential for nitroalkene compounds as drug candidates for STING modulation to treat STING-driven inflammatory diseases, providing new robust leads for preclinical development.
The Exercise for Fitness intervention is an approximately 11-minute video shown to participants which presents a fitness-based motivational frame for exercise and physical activity. Video content focuses on discussions related to the physical health effects of exercise, including cardiovascular health, increased calorie burning, and overall physical wellbeing. The video also includes recommendations for diversity of exercise, balancing cardiovascular and strength-training activities.
The invention relates to a medicinal composition for preventing and treating dust phthisis. The medicinal composition for preventing and treating dust phthisis is prepared from the following components in parts by weight: 27-33 parts of acanthopanax root, 13-18 parts of mulberry leaf, 5-10 parts of ginkgo, 7-14 parts of corsvenor momordica fruit, 10-15 parts of pearl barley, 18-23 parts of dandelion, 13-17 parts of bitter bamboo leaf, 3-8 parts of heartleaf houttuynia herb, 16-20 parts of common anemarrhena, 11-15 parts of common bletilla tuber, 15-18 parts of barbary wolfberry fruit and 10-15 parts of gecko. The medicinal composition for preventing and treating dust phthisis is low in price and definite in curative effect. By reasonably combining effective components and adjuvant components, supplementary and coordinative effects are achieved. The medicinal composition has the advantages of short treatment course, quick response and good curative effect. By combining pure natural raw medicaments, side effects, dependency and drug resistance are eliminated. The medicinal composition is widely suitable for the prevention, control and treatment of dust phthisis.
The invention relates to a common epitope of HA2 protein of multiple subtypes of influenza viruses, antibodies, an identification method and application, wherein the epitope can be combined with immune serum of H1, H3, H4, H5, H6, H7, H8, H9 and H10 subtypes of influenza viruses. An H5N1 subtype influenza strain S is selected, 18 polypeptides which are 20 amino acids in length and 10 amino acids overlapped with each other are designed according to the sequence of HA2 protein, the polypeptides are spotted to a modified silica gel mold after artificial synthesis to form a polypeptide chip, and antiserum aiming at different subtype IAVs is used for screening universal epitopes. Constructing the recombinant virus with the mutant epitope, and analyzing the binding capacity of the epitope and immune serum by western blot. The results show that 485-FYHKCDNECME-495 on HA2 protein HAs broad-spectrum binding activity with IAV antiserum of H1, H3, H4, H5, H6, H7, H8, H9 and H10 subtypes. K/D mutations in recombinant viruses result in reduced serum binding activity, indicating that they are key amino acids for serum binding activity. The peptide fragment also contains HLA-DR1 restricted CD 4T cell epitope.
PROBLEM TO BE SOLVED: To obtain a skin conditioning composition by including retinol or retinyl ester and a fatty acid amide. SOLUTION: This skin care composition contains (a) 0.001-10 wt.% of retinol and/or retinyl ester and (b) 0.0001-50 wt.% of a fatty acid amide (e.g. linoleoyl monoethanolamide). The fatty acid amide (neither free fatty acid nor fatty acid ester), through combined use with the retinol or retinyl ester, synergistically enhances keratinocyte proliferation and synergistically inhibits keratinocyte differentiation. This composition, which exhibits skin care effect equivalent to that of retinoic acid is usable as an alternative to retinoic acid, namely, without the need of using hard-to-prescribe and hard-to-stabilize retinoic acid. It is preferable that the weight ratios of the retinol to the fatty acid amide and of the retinyl ester to the fatty acid amide are (100:1) to (1:50) and (300:1) to (1:300), respectively.  This composition is effective for preventing/treating the dryness, photodamage, wrinkles, senile speckles, etc., of the skin.
### Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of CATAFLAM in patients with advanced renal disease. The renal effects of CATAFLAM may hasten the progression of renal dysfunction in patients with preexisting renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating CATAFLAM. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of CATAFLAM (see PRECAUTIONS: Drug Interactions). Avoid the use of CATAFLAM in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If CATAFLAM is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

### Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.